감염증 분야 제휴 및 라이선싱 계약, 2020년-2026년

Understand the infectious diseases partnering landscape using intelligence from 1,762 real-world collaboration and licensing deals.

Infectious Diseases Collaboration and Licensing Deals 2020-2026 provides comprehensive intelligence on 1,762 partnering deals involving infectious disease assets, technologies and development programs.

Infectious diseases partnering spans a highly diverse landscape, including vaccines, antivirals, antibiotics, anti-infectives, diagnostics and emerging technologies addressing established and newly emerging pathogens.

The report brings this activity together in one resource, enabling users to understand who is partnering, which infectious disease opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in infectious diseases partnering.

Understand the infectious diseases partnering landscape

The report analyzes infectious diseases dealmaking from 2020 to 2026, including:

• Trends in infectious diseases partnering by year
• Deal activity by deal type
• Industry sector
• Stage of development at the time of partnering
• Technology type
• Therapeutic indication
• Most active infectious diseases dealmakers
• Leading deals by disclosed value
• How infectious diseases partnering activity is evolving
• This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.
• Benchmark infectious diseases deal financials
• Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.

The report provides dedicated analysis of disclosed financial terms, including:

• Headline deal values
• Upfront payments
• Milestone payments
• Royalty rates
• Users can investigate the individual transactions behind these benchmarks to understand the wider context surrounding the disclosed economics.
• This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
• Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
• Identify leading infectious diseases dealmakers and prospective partners
• The report identifies the most active companies in infectious diseases partnering and provides transaction histories that enable users to investigate their previous activity.

This can help users identify:

• Companies actively seeking infectious disease opportunities
• Prospective licensing and collaboration partners
• Organizations repeatedly partnering in relevant disease areas
• Companies active at relevant stages of development
• Dealmakers demonstrating interest in specific pathogens, technologies or therapeutic approaches
• Competitors pursuing related external innovation strategies
• For companies seeking to partner an infectious disease asset or technology, previous transaction activity can provide valuable evidence of which organizations have demonstrated an appetite for comparable opportunities.
• Compare partnering activity across infectious disease indications and targets
• Infectious diseases encompass a wide variety of pathogens, indications and treatment or prevention approaches, each with differing scientific, clinical and commercial dynamics.
• The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad market-level benchmarks and focus on transactions most relevant to a particular program or strategic interest.
• Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
• Understand how infectious diseases agreements are structured
• The report includes collaboration, licensing, development, research and other partnering transactions.

Depending on the transaction and available disclosure, users can investigate areas including:

• Rights granted and retained
• Research and development responsibilities
• Licensing rights
• Exclusivity
• Geographic rights
• Intellectual property
• Development and regulatory obligations
• Manufacturing and supply responsibilities
• Commercialization rights
• Financial consideration
• Milestones and royalties
• Governance
• Term and termination provisions
• These real-world examples provide useful reference points when considering the appropriate structure for an infectious diseases partnership.
• Learn from real-world contract documents
• Where publicly available, the report provides access to underlying contract documents for selected infectious diseases transactions.

These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:

• Scope of rights
• Development obligations
• Intellectual property
• Exclusivity
• Financial terms
• Milestone triggers
• Royalty provisions
• Commercialization rights
• Termination and other negotiated provisions
• For teams preparing or negotiating an infectious diseases collaboration or licensing agreement, access to real contract language provides valuable insight into how comparable deals have been structured in practice.
• Comprehensive infectious diseases deal directory
• The report includes a comprehensive directory of 1,762 infectious diseases collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.

Deals can be reviewed by:

• Company
• Technology type
• Therapeutic indication or target
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable infectious diseases transactions, prospective partners and relevant deal structures.
• Search and Evaluation teams
• Understand which companies are actively seeking infectious disease opportunities across relevant indications, technologies and development stages.
• Biotechnology Companies Seeking Partners
• Identify organizations with demonstrated interest in comparable infectious disease assets, technologies and development programs.
• Corporate and R&D Strategy teams
• Understand how competitors and prospective partners are building infectious diseases portfolios through external innovation.
• Competitive and Market Intelligence teams
• Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
• Legal and Transaction teams
• Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
• Turn market-wide infectious diseases intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying infectious diseases deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in infectious diseases dealmaking

• 2.1. Introduction
• 2.2. Infectious diseases partnering over the years
• 2.3. Infectious diseases partnering by deal type
• 2.4. Infectious diseases partnering by industry sector
• 2.5. Infectious diseases partnering by stage of development
• 2.6. Infectious diseases partnering by technology type
• 2.7. Infectious diseases partnering by therapeutic indication

Chapter 3 - Financial deal terms for infectious diseases partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for infectious diseases partnering
• 3.3. Infectious diseases partnering headline values
• 3.4. Infectious diseases deal upfront payments
• 3.5. Infectious diseases deal milestone payments
• 3.6. Infectious diseases royalty rates

Chapter 4 - Leading infectious diseases deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in infectious diseases partnering
• 4.3. List of most active dealmakers in infectious diseases
• 4.4. Top infectious diseases deals by value

Chapter 5 - Infectious diseases contract document directory

• 5.1. Introduction
• 5.2. Infectious diseases partnering deals where contract document available

Chapter 6 - Infectious diseases dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by infectious diseases therapeutic target
• Deal directory
• Deal directory - Infectious diseases deals by company A-Z
• Deal directory - Infectious diseases deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Infectious diseases partnering since 2020
• Figure 2: Infectious diseases partnering by deal type since 2020
• Figure 3: Infectious diseases partnering by industry sector since 2020
• Figure 4: Infectious diseases partnering by stage of development since 2020
• Figure 5: Infectious diseases partnering by technology type since 2020
• Figure 6: Infectious diseases partnering by indication since 2020
• Figure 7: Infectious diseases deals with a headline value
• Figure 8: Infectious diseases deals with upfront payment values
• Figure 9: Infectious diseases deals with milestone payment
• Figure 10: Infectious diseases deals with royalty rates
• Figure 11: Active infectious diseases dealmaking activity since 2020
• Figure 12: Top infectious diseases deals by value since 2020